Select Page

BioPharma’s parent company Think Research progresses the digitization of Phase 1 clinical trials

Think Research Launches Electronic Data Capture System for its Clinical Research Phase 1 Business, BioPharma Services Inc.

TORONTO, ON, March 29, 2022 – Think Research Corporation (TSXV:THNK) (“Think” or the “Company”), a company focused on transforming healthcare through digital health software solutions, today announced the launch of its clinical trial Electronic Data Capture (“EDC”) platform, at  BioPharma Services Inc (“BioPharma”), a Think subsidiary.

This EDC launch creates a world-class application at BioPharma’s Phase 1 sites in Toronto and St Louis.  The EDC platform is expected to give BioPharma enhanced and superior capability to  capture Phase 1 data quicker with higher data quality. The use of this platform for Phase 1 activity is industry leading for BioPharma. The EDC platform will expedite clinical trial timelines, improve access to data for sponsors, and enable clients to shorten their drug development timelines to get therapeutics to the market faster. The EDC platform will be moving into the system validation stage with live clinic data to meet Current Good Clinical Practice (cGCP) standards in Toronto, Ontario, and St Louis, Missouri.

Renzo DiCarlo, President of Clinical Research at BioPharma said, “Our new EDC platform is leading edge in the Phase 1 clinical research space and has been designed to be easily adaptable and scalable for later stage clinical trials. We believe our clients will be delighted by the technology investments we are making.  This new digital application makes our Phase 1 clinics truly world class in the Phase 1 CRO industry segment.”

Sachin Aggarwal, CEO, Think said, “This new platform is part of the ongoing digital transformation of BioPharma that we announced as part of the acquisition in 2021. Think expects that the integration of technology into BioPharma’s clinical research business will lead to cost savings.  We are delivering a platform that will have a significant impact on the clinical research business.”

Saurabh Mukhi, Chief Technology Officer at Think stated, “Innovation in the clinical research space can only be made possible by combining teams of industry technology leaders with clinical research experts. The result is a platform that is built with the user’s experience in mind and is designed for the purpose of BioPharma’s clinical research business.”

About BioPharma Services Inc.

BioPharma Services Inc. is a full-service Contract Research Organization (CRO) specializing in the conduct of Phase I/IIa and Bioequivalence clinical trials for international pharmaceutical companies worldwide. BioPharma Services has clinical research facilities both in the USA and Canada with a total capacity of 300 beds with access to healthy volunteers and special populations. Headquartered in Toronto, Canada, BioPharma’s comprehensive services also include Bioanalysis at our GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Data Management and Medical Writing. For more information about BioPharma Services, please contact Ms. Anna Taylor, EVP of Commercial Operations at

About Think Research Corporation

Think Research is an industry leader in delivering knowledge-based digital healthcare software solutions. The Company’s focused mission is to organize the world’s health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process, standardize care, and improve patient outcomes. For over a decade, Think’s cloud-based, EMR-agnostic digital tools have empowered clinicians around the world and positively impacted millions of patients across the continuum of care – including primary physician care, acute care hospitals and surgical suites as well as community and seniors’ care. Think is proud to serve as a trusted health system partner to a rapidly growing, global client base that spans five continents across more than 13,000 healthcare facilities, with a clinical audience of over 300,000 doctors, nurses and pharmacists. Visit:


Click Here to read the full press release.

Popular Posts